Compare GSK plc (GSK) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Williams-Sonoma, Inc. — how do they compare? GSK plc trades at $50.56 (market cap $102.60B), while Williams-Sonoma, Inc. trades at $250.52 (market cap $29.51B). The key difference: GSK plc is far larger — about 3.5× Williams-Sonoma, Inc.'s market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | WSM | |
|---|---|---|
Market Cap | $102.60B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $251.81 |
52-Week Low | $38.22 | $168.64 |
Enterprise Value | $123.04B | $30.35B |
Dividend Yield | 3.57% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Williams-Sonoma (WSM) trades at $245.16, down 2.26% today, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 13.81% net income margin and 54.01% ROE, supported by recent earnings beats. Recent news highlights investor interest and a CEO stock sale, while cash flow trends show variability, with 2025 net cash flow at -$49 million.
Outlook remains positive with consistent earnings performance and a 'Moderate Buy' analyst consensus, though risks include consumer discretionary sector volatility and competitive pressures. The stock trades above the consensus price target of $231.10, suggesting limited near-term upside based on current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
